Unknown

Dataset Information

0

Ferrous iron-dependent delivery of therapeutic agents to the malaria parasite.


ABSTRACT: BACKGROUND:The malaria parasites Plasmodium falciparum and Plasmodium vivax generate significant concentrations of free unbound ferrous iron heme as a side product of hemoglobin degradation. The presence of these chemically reactive forms of iron, rare in healthy cells, presents an opportunity for parasite-selective drug delivery. Accordingly, our group is developing technologies for the targeted delivery of therapeutics to the intra-erythrocytic malaria parasite. These so-called 'fragmenting hybrids' employ a 1,2,4-trioxolane ring system as an iron(II)-sensing 'trigger' moiety and a 'traceless' retro-Michael linker to which a variety of partner drug species may be attached. After ferrous iron-promoted activation in the parasite, the partner drug is released via a ?-elimination reaction. METHODS:In this report, we describe three orthogonal experimental approaches that were explored in order to generate in vitro proof-of-concept for ferrous iron-dependent drug delivery from a prototypical fragmenting hybrid. CONCLUSION:Studies of two fragmenting hybrids by orthogonal approaches confirm that a partner drug species can be delivered to live P. falciparum parasites. A key advantage of this approach is the potential to mask a partner drug's intrinsic bioactivity prior to release in the parasite.

SUBMITTER: Mahajan SS 

PROVIDER: S-EPMC3574796 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ferrous iron-dependent delivery of therapeutic agents to the malaria parasite.

Mahajan Sumit S SS   Gut Jiri J   Rosenthal Philip J PJ   Renslo Adam R AR  

Future medicinal chemistry 20121201 18


<h4>Background</h4>The malaria parasites Plasmodium falciparum and Plasmodium vivax generate significant concentrations of free unbound ferrous iron heme as a side product of hemoglobin degradation. The presence of these chemically reactive forms of iron, rare in healthy cells, presents an opportunity for parasite-selective drug delivery. Accordingly, our group is developing technologies for the targeted delivery of therapeutics to the intra-erythrocytic malaria parasite. These so-called 'fragme  ...[more]

Similar Datasets

| S-EPMC3831501 | biostudies-literature
| S-EPMC3265971 | biostudies-literature
| S-EPMC4227544 | biostudies-other
| S-EPMC3697569 | biostudies-literature
| S-EPMC1222701 | biostudies-other
| S-EPMC5675029 | biostudies-literature
| S-EPMC4420023 | biostudies-literature
| S-EPMC7327978 | biostudies-literature
2012-02-29 | E-MEXP-3459 | biostudies-arrayexpress
| S-EPMC9263657 | biostudies-literature